 | • レポートコード：MRC23Q35753 • 出版社/出版日：QYResearch / 2023年3月 • レポート形態：英文、PDF、93ページ • 納品方法：Eメール（2-3日） • 産業分類：医薬品 |
| Single User | ￥435,000 (USD2,900) | ▷ お問い合わせ |
| Enterprise License | ￥870,000 (USD5,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは世界のADHD治療薬市場について調査・分析し、世界のADHD治療薬市場概要、市場トレンド、主要企業別競争状況、タイプ別セグメント分析（刺激薬、非刺激薬）、用途別セグメント分析（注意力欠如障害、多動・衝動制御障害、複合型）、地域別市場規模、主要企業のプロファイルなどに関する情報を掲載しています。主要企業としては、Takeda、Johnson & Johnson、Novartis、Eli Lilly、Tris Pharma, Inc、Neos Therapeutics、Mallinckrodt、Amneal Pharmaceuticals、Noven Pharmaceuticals、Purdue Parma、Zhengda Fenghaiなどが含まれています。 世界のADHD治療薬市場は、2022年にXXX米ドル、2029年にはXXX米ドルに達すると予測され、予測期間の年平均成長率はXXX％です。COVID-19とロシア・ウクライナ戦争の影響は、ADHD治療薬市場規模を推定する際に考慮しました。本レポートは、ADHD治療薬の世界市場を定量的・定性的な分析により包括的に提示し、読者がビジネス/成長戦略を策定し、市場競争状況を把握し、現在の市場における自社のポジションを分析し、ADHD治療薬に関するビジネス上の意思決定に役立てることを目的としています。 ・ADHD治療薬市場の概要 - ADHD治療薬のタイプ別セグメント - 世界のADHD治療薬市場規模：タイプ別分析（刺激薬、非刺激薬） - ADHD治療薬の用途別セグメント - 世界のADHD治療薬市場規模：用途別分析（注意力欠如障害、多動・衝動制御障害、複合型） - 世界のADHD治療薬市場規模予測（2018年-2029年） ・ADHD治療薬市場の成長トレンド - ADHD治療薬の地域別市場規模（2018年-2029年） - ADHD治療薬市場ダイナミクス - ADHD治療薬の業界動向 - ADHD治療薬市場の成長ドライバ、課題、阻害要因 ・主要企業別競争状況 - 企業別市場シェア - 世界の主要企業、業界ランキング分析 - 市場への参入、M＆A動向 ・タイプ別セグメント：刺激薬、非刺激薬 - 世界のADHD治療薬のタイプ別市場規模（2018年-2023年） - 世界のADHD治療薬のタイプ別市場規模（2024年-2029年） ・用途別セグメント：注意力欠如障害、多動・衝動制御障害、複合型 - 世界のADHD治療薬の用途別市場規模（2018年-2023年） - 世界のADHD治療薬の用途別市場規模（2024年-2029年） ・ADHD治療薬の地域別市場規模 - 北米のADHD治療薬市場規模（2018年-2029年） - アメリカのADHD治療薬市場規模（2018年-2029年） - ヨーロッパのADHD治療薬市場規模（2018年-2029年） - アジア太平洋のADHD治療薬市場規模（2018年-2029年） - 中国のADHD治療薬市場規模（2018年-2029年） - 日本のADHD治療薬市場規模（2018年-2029年） - 韓国のADHD治療薬市場規模（2018年-2029年） - インドのADHD治療薬市場規模（2018年-2029年） - オーストラリアのADHD治療薬市場規模（2018年-2029年） - 中南米のADHD治療薬市場規模（2018年-2029年） - 中東・アフリカのADHD治療薬市場規模（2018年-2029年） ・主要企業のプロファイル：企業情報、事業概要、売上、動向 Takeda、Johnson & Johnson、Novartis、Eli Lilly、Tris Pharma, Inc、Neos Therapeutics、Mallinckrodt、Amneal Pharmaceuticals、Noven Pharmaceuticals、Purdue Parma、Zhengda Fenghai ・アナリストの観点/結論 ・調査方法とデータソース |
Stimulants are the best and most common type of medication used to treat ADHD.
Highlights
The global ADHD Medication market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Johnson & Johnson is the largest manufacturer of ADHD medication in China, has a market share of over 40%. Other key players include Eli Lilly and Zhengda Fenghai, etc. Geographically speaking, East China is the largest market, has a market share of about 25%. In terms of type, both stimulants and non-stimulants account for about 50% of market share. In terms of application, hybrid is the dominant field using ADHD medication, has a market share of over 80%.
Report Scope
This report aims to provide a comprehensive presentation of the global market for ADHD Medication, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding ADHD Medication.
The ADHD Medication market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global ADHD Medication market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the ADHD Medication companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Takeda
Johnson & Johnson
Novartis
Eli Lilly
Tris Pharma, Inc
Neos Therapeutics
Mallinckrodt
Amneal Pharmaceuticals
Noven Pharmaceuticals
Purdue Parma
Zhengda Fenghai
Segment by Type
Stimulant
Non-stimulant
Segment by Application
Attention Deficit
Hyperactivity/impulse Control Disorder
Hybrid
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of ADHD Medication companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global ADHD Medication Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Stimulant
1.2.3 Non-stimulant
1.3 Market by Application
1.3.1 Global ADHD Medication Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Attention Deficit
1.3.3 Hyperactivity/impulse Control Disorder
1.3.4 Hybrid
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global ADHD Medication Market Perspective (2018-2029)
2.2 ADHD Medication Growth Trends by Region
2.2.1 Global ADHD Medication Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 ADHD Medication Historic Market Size by Region (2018-2023)
2.2.3 ADHD Medication Forecasted Market Size by Region (2024-2029)
2.3 ADHD Medication Market Dynamics
2.3.1 ADHD Medication Industry Trends
2.3.2 ADHD Medication Market Drivers
2.3.3 ADHD Medication Market Challenges
2.3.4 ADHD Medication Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top ADHD Medication Players by Revenue
3.1.1 Global Top ADHD Medication Players by Revenue (2018-2023)
3.1.2 Global ADHD Medication Revenue Market Share by Players (2018-2023)
3.2 Global ADHD Medication Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by ADHD Medication Revenue
3.4 Global ADHD Medication Market Concentration Ratio
3.4.1 Global ADHD Medication Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by ADHD Medication Revenue in 2022
3.5 ADHD Medication Key Players Head office and Area Served
3.6 Key Players ADHD Medication Product Solution and Service
3.7 Date of Enter into ADHD Medication Market
3.8 Mergers & Acquisitions, Expansion Plans
4 ADHD Medication Breakdown Data by Type
4.1 Global ADHD Medication Historic Market Size by Type (2018-2023)
4.2 Global ADHD Medication Forecasted Market Size by Type (2024-2029)
5 ADHD Medication Breakdown Data by Application
5.1 Global ADHD Medication Historic Market Size by Application (2018-2023)
5.2 Global ADHD Medication Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America ADHD Medication Market Size (2018-2029)
6.2 North America ADHD Medication Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America ADHD Medication Market Size by Country (2018-2023)
6.4 North America ADHD Medication Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe ADHD Medication Market Size (2018-2029)
7.2 Europe ADHD Medication Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe ADHD Medication Market Size by Country (2018-2023)
7.4 Europe ADHD Medication Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific ADHD Medication Market Size (2018-2029)
8.2 Asia-Pacific ADHD Medication Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific ADHD Medication Market Size by Region (2018-2023)
8.4 Asia-Pacific ADHD Medication Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America ADHD Medication Market Size (2018-2029)
9.2 Latin America ADHD Medication Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America ADHD Medication Market Size by Country (2018-2023)
9.4 Latin America ADHD Medication Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa ADHD Medication Market Size (2018-2029)
10.2 Middle East & Africa ADHD Medication Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa ADHD Medication Market Size by Country (2018-2023)
10.4 Middle East & Africa ADHD Medication Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Takeda
11.1.1 Takeda Company Detail
11.1.2 Takeda Business Overview
11.1.3 Takeda ADHD Medication Introduction
11.1.4 Takeda Revenue in ADHD Medication Business (2018-2023)
11.1.5 Takeda Recent Development
11.2 Johnson & Johnson
11.2.1 Johnson & Johnson Company Detail
11.2.2 Johnson & Johnson Business Overview
11.2.3 Johnson & Johnson ADHD Medication Introduction
11.2.4 Johnson & Johnson Revenue in ADHD Medication Business (2018-2023)
11.2.5 Johnson & Johnson Recent Development
11.3 Novartis
11.3.1 Novartis Company Detail
11.3.2 Novartis Business Overview
11.3.3 Novartis ADHD Medication Introduction
11.3.4 Novartis Revenue in ADHD Medication Business (2018-2023)
11.3.5 Novartis Recent Development
11.4 Eli Lilly
11.4.1 Eli Lilly Company Detail
11.4.2 Eli Lilly Business Overview
11.4.3 Eli Lilly ADHD Medication Introduction
11.4.4 Eli Lilly Revenue in ADHD Medication Business (2018-2023)
11.4.5 Eli Lilly Recent Development
11.5 Tris Pharma, Inc
11.5.1 Tris Pharma, Inc Company Detail
11.5.2 Tris Pharma, Inc Business Overview
11.5.3 Tris Pharma, Inc ADHD Medication Introduction
11.5.4 Tris Pharma, Inc Revenue in ADHD Medication Business (2018-2023)
11.5.5 Tris Pharma, Inc Recent Development
11.6 Neos Therapeutics
11.6.1 Neos Therapeutics Company Detail
11.6.2 Neos Therapeutics Business Overview
11.6.3 Neos Therapeutics ADHD Medication Introduction
11.6.4 Neos Therapeutics Revenue in ADHD Medication Business (2018-2023)
11.6.5 Neos Therapeutics Recent Development
11.7 Mallinckrodt
11.7.1 Mallinckrodt Company Detail
11.7.2 Mallinckrodt Business Overview
11.7.3 Mallinckrodt ADHD Medication Introduction
11.7.4 Mallinckrodt Revenue in ADHD Medication Business (2018-2023)
11.7.5 Mallinckrodt Recent Development
11.8 Amneal Pharmaceuticals
11.8.1 Amneal Pharmaceuticals Company Detail
11.8.2 Amneal Pharmaceuticals Business Overview
11.8.3 Amneal Pharmaceuticals ADHD Medication Introduction
11.8.4 Amneal Pharmaceuticals Revenue in ADHD Medication Business (2018-2023)
11.8.5 Amneal Pharmaceuticals Recent Development
11.9 Noven Pharmaceuticals
11.9.1 Noven Pharmaceuticals Company Detail
11.9.2 Noven Pharmaceuticals Business Overview
11.9.3 Noven Pharmaceuticals ADHD Medication Introduction
11.9.4 Noven Pharmaceuticals Revenue in ADHD Medication Business (2018-2023)
11.9.5 Noven Pharmaceuticals Recent Development
11.10 Purdue Parma
11.10.1 Purdue Parma Company Detail
11.10.2 Purdue Parma Business Overview
11.10.3 Purdue Parma ADHD Medication Introduction
11.10.4 Purdue Parma Revenue in ADHD Medication Business (2018-2023)
11.10.5 Purdue Parma Recent Development
11.11 Zhengda Fenghai
11.11.1 Zhengda Fenghai Company Detail
11.11.2 Zhengda Fenghai Business Overview
11.11.3 Zhengda Fenghai ADHD Medication Introduction
11.11.4 Zhengda Fenghai Revenue in ADHD Medication Business (2018-2023)
11.11.5 Zhengda Fenghai Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details